News Related to Trough Concentration

Related coverage linked through entity extraction aliases.

FDA approves once-monthly subcutaneous amivantamab dosing in EGFR-mutated NSCLC

Apr 16, 2026

The FDA approved once-monthly subcutaneous amivantamab with lazertinib for first-line EGFR-mutated advanced NSCLC. PALOMA-2 showed high response rates and no new safety signals.

FDA Approves 46 Novel Drugs in 2025, Small Molecules Lead with 31 Approvals

May 01, 2025

The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.